Trexquant Investment LP boosted its position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 27.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 98,206 shares of the medical device company's stock after purchasing an additional 20,875 shares during the period. Trexquant Investment LP owned approximately 0.20% of AtriCure worth $3,001,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its stake in shares of AtriCure by 1.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 394,584 shares of the medical device company's stock valued at $11,064,000 after acquiring an additional 5,812 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in AtriCure by 38.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,053 shares of the medical device company's stock valued at $394,000 after purchasing an additional 3,880 shares during the last quarter. Captrust Financial Advisors acquired a new stake in AtriCure during the 3rd quarter valued at approximately $230,000. State Street Corp increased its holdings in AtriCure by 4.9% during the 3rd quarter. State Street Corp now owns 1,344,856 shares of the medical device company's stock worth $37,710,000 after purchasing an additional 63,002 shares during the last quarter. Finally, Two Sigma Advisers LP raised its position in shares of AtriCure by 14.6% in the 3rd quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company's stock valued at $18,621,000 after purchasing an additional 84,700 shares in the last quarter. Hedge funds and other institutional investors own 99.11% of the company's stock.
Insider Activity at AtriCure
In other news, Director Karen Prange sold 6,100 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the transaction, the director now directly owns 17,828 shares in the company, valued at approximately $679,603.36. The trade was a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 3.20% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on ATRC shares. JPMorgan Chase & Co. dropped their price target on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating for the company in a research note on Thursday, March 27th. JMP Securities reissued a "market outperform" rating and issued a $60.00 target price on shares of AtriCure in a research report on Monday, February 10th. Canaccord Genuity Group cut their target price on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating on the stock in a research note on Friday, March 28th. Piper Sandler lifted their price target on AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $51.00 price objective on shares of AtriCure in a report on Thursday, March 27th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $49.44.
Check Out Our Latest Research Report on AtriCure
AtriCure Stock Performance
ATRC stock traded up $0.43 during midday trading on Friday, reaching $32.07. The company had a trading volume of 331,646 shares, compared to its average volume of 667,282. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. The stock has a 50 day moving average price of $36.01 and a 200 day moving average price of $34.27. The firm has a market capitalization of $1.57 billion, a PE ratio of -33.76 and a beta of 1.65. AtriCure, Inc. has a fifty-two week low of $18.94 and a fifty-two week high of $43.11.
About AtriCure
(
Free Report)
AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.
See Also
Before you consider AtriCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AtriCure wasn't on the list.
While AtriCure currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
